atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917 Post published:January 12, 2023 Post category:Press Release
Bright Minds Biosciences Announces Resignation of Board Member Post published:January 12, 2023 Post category:Press Release
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses Post published:January 12, 2023 Post category:Press Release
Optimi Health Announces Re-Appointments to Board of Directors Post published:January 12, 2023 Post category:Press Release
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial Post published:January 12, 2023 Post category:Press Release
PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation Post published:January 8, 2023 Post category:Press Release
GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates Post published:January 7, 2023 Post category:Press Release
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression Post published:January 6, 2023 Post category:Press Release
Reunion Neuroscience Inc. Provides 2023 Corporate Update Post published:January 6, 2023 Post category:Press Release
FILAMENT HEALTH ANNOUNCES CEO YEAR END LETTER AND CHANGE TO BOARD OF DIRECTORS Post published:January 5, 2023 Post category:Press Release